# Angiotensin Receptor Blockers in Aortic Stenosis

Study · id `cardio:ct-nct04913870` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04913870](<https://clinicaltrials.gov/study/NCT04913870>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04913870

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 144 participants.

## Technical summary

Registry record NCT04913870. Randomized; quadruple masking; primary purpose treatment. Start 2020-02-01 (actual); primary completion 2027-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 144 participants (planned count; ClinicalTrials.gov record NCT04913870, source copy `cardio:ctgov-nct04913870-2024-12-20`, retrieved 2026-10-26)
- Started: 2020-02-01 (actual) (ClinicalTrials.gov record NCT04913870, source copy `cardio:ctgov-nct04913870-2024-12-20`, retrieved 2026-10-26)
- Primary completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT04913870, source copy `cardio:ctgov-nct04913870-2024-12-20`, retrieved 2026-10-26)
- Completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT04913870, source copy `cardio:ctgov-nct04913870-2024-12-20`, retrieved 2026-10-26)
- Countries: Canada; Denmark (ClinicalTrials.gov record NCT04913870, source copy `cardio:ctgov-nct04913870-2024-12-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04913870-2024-12-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Angiotensin Receptor Blockers in Aortic Stenosis
- Acronym: ARBAS
- Condition: Aortic Stenosis
- Condition: Aortic Valve Stenosis
- Intervention (Drug): Angiotensin Receptor Blockers
- Intervention (Other): Placebo
- Lead sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Lead sponsor class: OTHER
- Collaborator: Odense University Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- Registry lists this organization as the lead sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval (`cardio:org-institut-universitaire-de-cardiologie-et-de-pneumologie-de-ac9f54`)
- Registry lists this organization as a collaborator: Odense University Hospital (`cardio:org-odense-university-hospital`)

## Provenance

Content hash: 82b3e7fe735bad4820a2d028d9f4eca83a3b0bc7dd0038b1c5d3a9b0e3b7c6ae
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
